References

1. The World Health Organization Web Site. Epidemic and Pandemic Alert and Response (EPR). Avian influenza. Current WHO phase of pandemic alert. Available at: http://www.who.int/csr/disease/avian_influenza/
   phase/en/index.html. Accessed May 1, 2007.
    
2. Centers for Disease Control and Prevention Web Site. Influenza (Flu). Seasonal Flu. What You Should Know. Q&A: The Disease. Available at: http://www.cdc.gov/flu/about/qa/disease.htm. Accessed May 1, 2007.
    
3. Centers for Disease Control and Prevention Web Site. Prevention and Control of Influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep. 2006 Jul 28;55(RR10):1-42. Available at: http://www.cdc.gov/mmwr/PDF/rr/rr5510.pdf. Accessed May 1, 2007.
    
4. Blaser MJ. Pandemics and Preparations. J Infect Dis. 2006;194:S70-72.
    
5. Moscana A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005;353:1363-73.
    
6. Centers for Disease Control and Prevention Web Site. Influenza (Flu). Seasonal Flu. What You Should Know. Key Facts about Influenza and the Influenza Vaccine. Available at: http://www.cdc.gov/flu/keyfacts.htm. Accessed May 1, 2007.
    
7. Centers for Disease Control and Prevention Web Site. Influenza (Flu). Good Health Habits for Preventing the Flu. Available at: http://www.cdc.gov/flu/protect/habits.htm. Accessed May 1, 2007.
    
8. Kilbourne ED. Influenza pandemics of the 20th century. Emerg Infect Diseases. 2006;12:9-14.
    
9. The World Health Organization Web Site. Epidemic and Pandemic Alert and Response (EPR). Avian influenza. Avian influenza frequently asked questions. Available at: http://www.who.int/csr/disease/avian_influenza/avian_faqs/
   en/index.html#areall. Accessed May 1, 2007.
    
10. US Department of Health and Human Services. Pandemicflu.gov Web Site. Frequent Questions (FAQs). Pandemic Influenza Questions. Why are pandemics such dreaded events? Available at: http://www.pandemicflu.gov/faq/pandemicinfluenza/1108.html. Accessed May 5, 2007.
     
11. Temte JL. Preparing for an influenza pandemic: vaccine prioritization. Fam Pract Manag. 2006;13(1):32-34. Available at: http://aafp.org/fpm/20060100/32prep.html#refs. Accessed May 1, 2007.
     
12. Centers for Disease Control and Prevention Web Site. Avian Influenza (Flu). Key Facts About Avian Influenza (Bird Flu) and Avian Influenza A (H5N1) Virus. Available at:
    http://www.cdc.gov/flu/avian/gen-info/facts.htm
    Accessed May 1, 2007.
     
13. US Department of Health and Human Services. Pandemicflu.gov Web Site. Frequent Questions (FAQs). Pandemic Influenza Questions. How do pandemic viruses spread? Available at: http://www.pandemicflu.gov/faq/pandemicinfluenza/1070.html. Accessed May 5, 2007.
     
14. The World Health Organization Web Site. Epidemic and Pandemic Alert and Response (EPR). Influenza. Pandemic preparedness. Available at: http://www.who.int/csr/disease/influenza/pandemic/en/index.html. Accessed May 1, 2007.
     
15. US Department of Health and Human Services. Pandemicflu.gov Web Site. Frequent Questions (FAQs). Pandemic Influenza Questions. What age groups are most likely to be affected during an influenza pandemic? Available at: http://www.pandemicflu.gov/faq/pandemicinfluenza/1080.html. Accessed May 5, 2007.
     
16. Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Diseases. 1999;5(5):1-19. Available at: http://www.cdc.gov/ncidod/EID/vol5no5/meltzer.htm. Accessed May 1, 2007.
     
17. US Department of Health and Human Services. Pandemicflu.gov Web Site. Economic impacts. Available at: http://www.pandemicflu.gov/impacts/index.html. Accessed May 5, 2007.
     
18. The World Health Organization Web Site. Epidemic and Pandemic Alert and Response (EPR). Avian influenza. Vaccine research and development: current status. Available at: http://www.who.int/csr/disease/avian_influenza/
    vaccineresearch2005_11_3/en/index.html. Accessed May 1, 2007.
     
19. FDA approves first US vaccine for humans against the avian influenza virus H5N1 [press release]. US Food and Drug Administration; April 17, 2007.
     
20. US Department of Health and Human Services. Pandemicflu.gov Web Site. Workplace planning. Overview. Available at: http://www.pandemicflu.gov/plan/workplaceplanning/
    index.html#overview. Accessed May 5, 2007.
     
21. US Department of Health and Human Services. Pandemic Planning Update. A report from Secretary Michael O. Leavitt. March 13, 2006. Available at: www.pandemicflu.gov. Accessed May 1, 2007.
     
22. The White House. National Strategy for Pandemic Influenza. President’s Letter. November 1, 2005. Available at: http://www.whitehouse.gov/homeland/pandemic-influenza.html. Accessed May 1, 2007.
     
23. US Department of Health and Human Services. HHS Pandemic Influenza Plan Fact Sheet. November 2, 2005. Available at: http://www.hhs.gov/pandemicflu/plan/factsheet.html. Accessed May 1, 2007.
     
24. US Department of Labor. Occupational Safety and Health Administration. Guidance on Preparing Workplaces for an Influenza Pandemic. 2007. Available at: http://www.osha.gov/Publications/influenza_pandemic.html
    #organizations_protect. Accessed May 1, 2007.
     
25. Center for Infectious Disease Research & Policy. 2006 Summit Coverage: Conference poll: 18% of businesses have pandemic plan. February 15, 2006. Available at: http://www.cidrap.umn.edu/cidrap/content/influenza/
    biz-plan/news/feb1506survey.htm. Accessed May 1, 2007.
     
26. Center for Infectious Disease Research & Policy. GAO says financial markets not ready for pandemic. May 2, 2007. Available at: http://www.cidrap.umn.edu/cidrap/content/influenza/
    panflu/news/may0207gao.html. Accessed May 1, 2007.
     
27. US Department of Health and Human Services. Business Pandemic Influenza Planning Checklist. Available at: http://www.pandemicflu.gov/plan/pdf/businesschecklist.pdf. Accessed May 1, 2007.
     
28. The World Health Organization Web Site. Epidemic and Pandemic Alert and Response (EPR). Influenza. Pandemic preparedness. WHO Guidelines on the Use of Vaccines and Antivirals during Influenza Pandemics. Available at: http://www.who.int/csr/resources/
    publications/influenza/11_29_01_A.pdf. Accessed May 1, 2007.
     
29. US Department of Health and Human Services. Pandemicflu.gov Web Site. Frequently Asked Questions (FAQS). Antivirals Questions. What antiviral drugs are available for treatment of seasonal and avian influenza? Available at: http://www.pandemicflu.gov/faq/antivirals/1100.html. Accessed May 1, 2007.
     
30. US Department of Health and Human Services. Pandemicflu.gov Web Site. Tests, Vaccines, Medications & Masks. Masks/Respirators. Available at: http://www.pandemicflu.gov/vaccine/mask.html. Accessed May 1, 2007.
     
31. US Department of Health and Human Services. Pandemicflu.gov Web Site. Community Planning. Community Strategy for Pandemic Influenza Mitigation. Available at: http://www.pandemicflu.gov/plan/community/
    commitigation.html. Accessed May 1, 2007.
     
32. Whitley RJ, Bartlett J, Hayden FG, et al. Seasonal and pandemic influenza: recommendations for preparedness in the United States. J Infect Dis. 2006;194(suppl 2):S155-S161.
     
33. US Dept of Health and Human Services. Pandemic planning update III. November 13, 2006. http://www.pandemicflu.gov/plan/pdf/panflureport3.pdf. Accessed January 22, 2007.
     
34. Osterholm MT. Preparing for the next pandemic. N Engl J Med. 2005;352(18):1839-1842.
     
35. Trust for America’s Health. Pandemic flu and the potential for US economic recession: a state-by-state analysis. March 2007. http://healthyamericans.org/reports/flurecession/FluRecession.pdf. Accessed May 2, 2007.
     
36. US Congress, Congressional Budget Office. A potential influenza pandemic: an update on possible macroeconomics effects policy issues. Revised July 27, 2006. http://www.cbo.gov/ftpdocs/72xx/
    doc7214/05-22-Avian Flu.pdf. Accessed November 20, 2006.
     
37. US Congress, Congressional Budget Office. A potential influenza pandemic: possible macroeconomic effects and policy issues. Revised July 27, 2006. http://www.cbo.gov/ftpdocs/69xx/doc6946/12-08-Birdflu.pdf. Accessed November 20, 2006.
     
38. RELENZA (zanamivir for inhalation) prescribing information.
     
39. Gubareva LV, Matrosovich MN, Brenner MK, et al. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis. 1998 Nov;178(5):1257-1262.
     
40. Wetherall NT, Trivedi T, Zeller J, et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol. 2003;41(2):742-750.
     
41. de Jong MD, Thanh TT, Khanh TH, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med. 2005;353(25):2667-2672.

 
Important Safety Information About RELENZA

• Serious cases of bronchospasm, including fatalities, have been reported during treatment with RELENZA in patients with and without underlying airway disease. Many of these cases were reported during postmarketing, and causality was difficult to assess
  
• RELENZA SHOULD BE DISCONTINUED IN ANY PATIENT WHO DEVELOPS BRONCHOSPASM OR DECLINE IN RESPIRATORY FUNCTION; immediate treatment and hospitalization may be required
  
• Safety and efficacy have not been demonstrated in patients with high-risk underlying medical conditions
  
• Patients should be instructed in the use of the delivery system. Instructions should include a demonstration whenever possible
  
• If treatment with RELENZA is considered for a patient with underlying airway disease, the potential risks and benefits should be carefully weighed. If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care including availability of fast-acting bronchodilators
  
• Common adverse events in treatment and prophylaxis studies with RELENZA were nausea, diarrhea, sinusitis, viral respiratory infections, headaches, nasal signs and symptoms. The incidence of these adverse events was similar in both groups for RELENZA and placebo-treated groups
  
• Please see complete Prescribing Information for RELENZA